Jay Flatley On Sequencing, Cancer, and FDA

Aug 19, 2010

The San Diego Union-Tribune's Keith Darcé recently spoke with Illumina CEO Jay Flatley about the company's share in the sequencing market, its lowered whole-genome sequencing price, its plans to develop diagnostic tests for certain cancers, and its recent involvement with the US Food and Drug Administration's push to regulate DTC genetic testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Keep It (Partly) Virtual

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

For Cross-Protection

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Proteomics of Severity

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Genome Biology Papers on Regulatory Element, Single-Cell Integration, Sequence Simulation Tools

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.

Menu